An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene

Lung Cancer

Volumn 81, Issue 3, 2013, Pages 487-490

  Toyokawa, Gouji ^a   Takenoyama, Mitsuhiro ^a   Taguchi, Kenichi ^a   Toyozawa, Ryo ^a   Inamasu, Eiko ^a   Kojo, Miyako ^a   Shiraishi, Yoshimasa ^a   Morodomi, Yosuke ^a   Takenaka, Tomoyoshi ^a   Hirai, Fumihiko ^a   Yamaguchi, Masafumi ^a   Seto, Takashi ^a   Shimokawa, Mototsugu ^a   Ichinose, Yukito ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

EML4 ALK; Oncogenic driver mutation; Small cell lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CISPLATIN; ETOPOSIDE; MICROTUBULE ASSOCIATED PROTEIN 4;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; FEMALE; FUSION GENE; GENETIC VARIABILITY; HUMAN; IMMUNOREACTIVITY; LUNG; LUNG BIOPSY; LUNG SMALL CELL CANCER; PLEURA EFFUSION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THORAX RADIOGRAPHY;

EML4-ALK; ONCOGENIC DRIVER MUTATION; SMALL-CELL LUNG CANCER;

ADULT; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOME BREAKPOINTS; FEMALE; GENETIC VARIATION; HUMANS; LUNG NEOPLASMS; ONCOGENE PROTEINS, FUSION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84881664426     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.05.022     Document Type: Article

References (17)

1. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
2. Mok T.S. Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 2011, 8:661-668.
3. Mitsudomi T., Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007, 98:1817-1824.
4. Hammerman P.S., Lawrence M.S., Voet D., Jing R., Cibulskis K., Sivachenko A., et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
5. Peifer M., Fernandez-Cuesta L., Sos M.L., George J., Seidel D., Kasper L.H., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012, 44:1104-1110.
6. Toyokawa G., Taguchi K., Ohba T., Morodomi Y., Takenaka T., Hirai F., et al. First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component. J Thorac Oncol 2012, 7:e39-e41.
7. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
8. Tatematsu A., Shimizu J., Murakami Y., Horio Y., Nakamura S., Hida T., et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 2008, 14:6092-6096.
9. Murakami Y., Mitsudomi T., Yatabe Y. A Screening Method for the ALK Fusion Gene in NSCLC. Front Oncol 2012, 2:24.
10. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
11. Christensen C.L., Zandi R., Gjetting T., Cramer F., Poulsen H.S. Specifically targeted gene therapy for small-cell lung cancer. Expert Rev Anticancer Ther 2009, 9:437-452.
12. Koh Y., Kim D.W., Kim T.M., Lee S.H., Jeon Y.K., Chung D.H., et al. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. J Thorac Oncol 2011, 6:905-912.
13. Kaufmann O., Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology 2000, 36:415-420.
14. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346:85-91.
15. Okamoto H., Watanabe K., Kunikane H., Yokoyama A., Kudoh S., Asakawa T., et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007, 97:162-169.
16. Takeda M., Okamoto I., Sakai K., Kawakami H., Nishio K., Nakagawa K. Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Ann Oncol 2012, 23:2931-2936.
17. Lee H.Y., Ahn H.K., Jeong J.Y., Kwon M.J., Han J.H., Sun J.M., et al. Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. Lung Cancer 2013, 79:40-45.